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A B S T R A C T
Phenylketonuria (PKU) is an inherited metabolic disease caused by phenylalanine hydroxylase (PAH) deficiency.
As the resulting high blood phenylalanine (Phe) concentration can have detrimental effects on brain develop-
ment and function, international guidelines recommend lifelong control of blood Phe concentration with dietary
and/or medical therapy. Sapropterin dihydrochloride is a synthetic preparation of tetrahydrobiopterin (6R-
BH4), the naturally occurring cofactor of PAH. It acts as a pharmacological chaperone, reducing blood Phe
concentration and increasing dietary Phe tolerance in BH4-responsive patients with PAH deficiency. Protocols to
establish responsiveness to sapropterin dihydrochloride vary widely.
Two meetings were held with an international panel of clinical experts in PKU management to develop
recommendations for sapropterin dihydrochloride response testing. At the first meeting, regional differences and
similarities in testing practices were discussed based on guidelines, a literature review, outcomes of a global
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physician survey, and case reports. Statements developed based on the discussions were sent to all participants
for consensus (> 70% of participants) evaluation using a 7-level rating system, and further discussed during the
second meeting.
The experts recommend sapropterin dihydrochloride response testing in patients with untreated blood Phe
concentrations of 360–2000 μmol/L, except in those with two null mutations. For neonates, a 24-h sapropterin
dihydrochloride loading test is recommended; responsiveness is defined as a decrease in blood Phe ≥30%. For
older infants, children, adolescents, and adults, a test duration of ≥48 h or a 4-week trial is recommended. The
main endpoint for a 48-h to 7-day trial is a decrease in blood Phe, while improved Phe tolerance is the endpoint
to be assessed during a longer trial. Longer trials may not be feasible in some locations due to lack of re-
imbursement for hospitalization, while a 4-week trial may not be possible due to limited access to sapropterin
dihydrochloride or public health regulation. A 48-h response test should be considered in pregnant patients who
cannot achieve blood Phe ≤360 μmol/L with a Phe-restricted diet. Durability of response and clinical benefits of
sapropterin dihydrochloride should be assessed over the long term. Harmonization of protocols is expected to
improve identification of responders and comparability of test results worldwide.
1. Introduction
Phenylketonuria (PKU) is a rare autosomal recessive metabolic
disorder caused by deficiency of the enzyme phenylalanine hydroxylase
(PAH; EC 1.14.16.1). PAH deficiency results in a complete or partial
inability to convert phenylalanine (Phe) to tyrosine (Tyr) in the liver,
leading to high blood Phe (hyperphenylalaninemia, HPA), which can
cross the blood-brain barrier [1]. Exposure of the brain to high Phe
concentrations can have detrimental effects on brain development and
function [2,3]. Without treatment, PKU can result in irreversible in-
tellectual disability, behavioral problems, psychiatric symptoms, motor
deficits, seizures, and eczematous rash [1–3]. Patients with PKU are
genotypically and phenotypically diverse. As of June 28, 2018, the
Phenylalanine Hydroxylase Gene Locus-Specific Database described
1044 known variations in the human PAH gene (http://www.biopku.
org). Phenotypes can vary from mild HPA to severe phenotypes with
untreated blood Phe concentrations exceeding 1200 μmol/L, also re-
ferred to as classical PKU [1]. The prevalence of PKU varies widely
across the world, from 1 out of every 4000 live births in Turkey [4]
to< 1 out of 200,000 live births reported for Thailand [1,5].
With the advent of newborn screening programs for PKU and
widespread implementation of early control of blood Phe concentra-
tion, the most severe neuropsychological complications of the disease
can be prevented [1,6]. In potential cases identified by newborn
screening, inherited disorders of BH4 metabolism, liver diseases, and
DnaJ heat shock protein family (Hsp40) member C12 (DNAJC12) de-
ficiency that can also result in elevated blood Phe concentrations must
be ruled out [6,7]. Patients with DNAJC12 deficiency show HPA, but
have a normal PAH gene and normal levels and proportions of pterins
in urine and blood. Diagnosis can be confirmed by evaluation of the Phe
concentration, Phe:Tyr ratio, and complete amino acid profile in plasma
[3]. Deficiencies of BH4 metabolism should be excluded by measuring
relative levels of pterins (neopterin, biopterin, and primapterin) in
blood or urine and dihydropteridine reductase activity in dried blood
spots [2,8]. To prevent brain damage, American and European guide-
lines for the management of PKU recommend lifelong control of blood
Phe concentration, starting as soon as possible after birth [2,3].
Whereas the American guidelines recommend to maintain blood Phe
concentration in the range of 120–360 μmol/L in patients of all ages
[3], the European guidelines advise to keep blood Phe below 360 μmol/L
in children until the age of 12 years and in pregnant women, and below
600 μmol/L in (non-pregnant) patients older than 12 years [2].
Treatment strategies for PKU aim at lowering blood Phe con-
centration by dietary and/or pharmacologic therapy. Dietary therapy
consists of a Phe-restricted diet in combination with Phe-free or Phe-
restricted L-amino acid-rich medical foods and/or modified low-protein
foods [3,9]. However, a strict Phe-restricted diet is very difficult to
maintain in the long term, particularly for adolescents and adults [1]. A
synthetic preparation of 6R-BH4, the naturally occurring cofactor of
PAH, is available as sapropterin dihydrochloride (Kuvan®, BioMarin
Pharmaceutical Inc., Novato, CA, USA). Sapropterin dihydrochloride
was approved by the Food and Drug Administration (FDA) in 2007 and
the European Medicines Agency (EMA) in 2008 for the treatment of
HPA in patients with BH4-responsive PKU or BH4 deficiencies [10,11].
It was subsequently approved by both regulatory agencies for the
treatment of all patients, including children<4 years of age [10,11].
The drug is available as 100mg tablets and powder (100 and 500mg)
for oral solution. Availability of formulations and reimbursement varies
between countries. In patients with BH4-responsive PKU, clinical trials
of sapropterin dihydrochloride have demonstrated significant reduc-
tions in blood Phe concentration, increased Phe tolerance, and good
long-term tolerability [12–17]. The benefits of sapropterin dihy-
drochloride are bestowed by aiding patients, in concert with a Phe-
restricted diet, to achieve lower blood Phe concentrations. In patients
with good metabolic control, it allows the inclusion of more natural
protein in the diet, while maintaining blood Phe concentration in the
target range (i.e. increased Phe tolerance). Improvements in attention
deficit hyperactivity disorder (ADHD) inattentive symptoms and ex-
ecutive function have also been associated with sapropterin dihy-
drochloride treatment [12–17]. To identify those patients who would
benefit from treatment, a sapropterin dihydrochloride response test or
trial can be performed [18]. Originally, the BH4 response test was only
used for differential diagnosis, to discriminate between patients with
PAH deficiency and disorders of BH4 metabolism [6]. However, since
the approval of sapropterin dihydrochloride for the treatment of PKU,
centers across the world have adapted the test to evaluate responsive-
ness to the drug.
There is a wide variety in protocols used to establish responsiveness
between and even within countries, as illustrated by a literature review
of studies on this subject (Additional file 1). The literature review re-
veals that testing protocols differ, particularly with regard to test
duration (from 8 h to several weeks), Phe loading strategies before sa-
propterin dihydrochloride testing, and diet requirements during the
test. More similarities were seen for other aspects of the testing pro-
tocol. The majority of studies used a sapropterin dihydrochloride dose
of 20mg/kg, taken either one time or daily for several days, which was
found to be associated with greater responsiveness rates than a 10mg/
kg dose [19,20]. In addition, most studies defined responsiveness as
a≥ 30% reduction in blood Phe concentration. Some general conclu-
sions could be made with regard to the impact of phenotype, genotype,
and test duration on BH4 responsiveness. Although patients with milder
phenotypes (lower baseline blood Phe concentration before start of any
treatment) appeared to respond better to BH4 than more severe phe-
notypes, responders were identified across the disease spectrum
(Fig. 1). Genotype-phenotype correlation studies have shown that
genotype determines residual PAH activity and may help determine
BH4 responsiveness in some instances: whereas two null-mutations are
highly predictive of non-responsiveness, missense mutations in the
oligomerization domain appear to predict responsiveness [21–24].
Studies comparing different response periods suggested that an 8-h test
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is too short to identify all responders and that most, but not all, patients
respond to BH4 within 24 h. A study by Anjema et al. suggested that a
positive 8-h neonatal response test also predicts responsiveness in the
long term, but that a negative 8-h neonatal response test does not rule
out responsiveness in a 48-h response test performed at an older age
[25]. In addition, a retrospective study by the same investigators in a
cohort of 177 (non‑neonatal) patients showed that a 48-h test is a good
predictor of responsiveness in the long term, although patients who
only respond> 24 h after the first BH4 dosing are more likely to be
false responders [26].
The wide variety in sapropterin dihydrochloride response testing
practices suggested by the literature review is confirmed by the out-
comes of the Global BH4 (KUVAN®) Response Survey, an online phy-
sician survey that assessed differences and similarities in testing prac-
tices between regions worldwide (Additional file 2). The analysis
focused on 73 participants who trialed a higher proportion of their PKU
patients than their respective regional medians. The outcomes of the
survey showed considerable differences between the regions (Europe
and Middle East [EUMEA, n=40], Asia and Pacific [APAC, n=25],
and Latin America [LATAM, n=8]; no participants from the USA were
included in the survey), particularly with regard to test duration, target
blood Phe concentration, and definitions used to identify partial re-
sponders to sapropterin dihydrochloride. In general, most participants
do not exclude patients from sapropterin dihydrochloride response
testing, although 40–50% use selection criteria to determine which
patients are recommended for a trial. The most frequently used selec-
tion criteria were blood Phe concentration and increased disease se-
verity. In addition, the participants tend to utilize short protocol
durations (24–72 h), but with a wide variability between regions
(Fig. 2). Most participants collect 2–5 Phe measurements prior to
testing and 4–5 measurements during testing (independent of protocol
duration), and use an initial sapropterin dihydrochloride dose of
20mg/kg. Sapropterin dihydrochloride response was most commonly
defined as a 30% reduction in blood Phe concentration relative to
baseline. Whereas increased Phe tolerance was the criterion used to
determine durability of response, non-responders were mostly dis-
continued from treatment. While results for LATAM were often not in
line with those of EUMEA and APAC, it should be noted that these
results were based on answers from only eight participants. The limited
availability of sapropterin dihydrochloride in LATAM greatly limited
the number of clinicians experienced with this medication.
The great variety between countries and regions in sapropterin di-
hydrochloride response testing practices can, at least partly, be ex-
plained by the lack of worldwide guidelines for response testing and the
lack of comparison studies. Until now, guidelines published in peer-
reviewed international journals only exist for Europe and the USA
Fig. 1. Responsiveness to tetrahydrobiopterin (BH4) according to phenotype in 23 prospective studies including ≥20 patients [12,19,23,27–46]. See Additional file
1 for more detailed information on the studies. MHP: Mild hyperphenylalaninemia; PKU: phenylketonuria.
Fig. 2. Most frequently utilized protocol (1 per participant) in the Global BH4 Response Survey (see Additional file 2). Data in the graph are based on answers to the
question “What is the duration of your most frequently utilized protocol for BH4 response testing?”. The survey did not include participants from the US, where the
standard procedure is a 4-week (30 day) trial. APAC: Asia and Pacific; EUMEA: Europe and Middle East; LATAM: Latin America.
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(Table 1) [2,3,6,47,48]. The protocols suggested in these guidelines
differ considerably, particularly with regard to test duration and defi-
nition of responsiveness (Table 1). Differences in test protocols may also
be due to differences between countries in reimbursement policies.
Whereas some countries do not allow hospitalization of patients for
response testing, it is common practice elsewhere. In addition, in some
countries it is not possible to obtain reimbursement for a long trial, or it
can take months before patients get reimbursement for treatment after
a successful response test. Differences also exist with regard to la-
boratory newborn screening practices for PKU and the laboratories'
interface with clinical units, particularly in regard to the timing of when
clinicians become aware of the results.
To increase uniformity in sapropterin dihydrochloride response
testing practices for patients with PKU worldwide, an international
panel of experts gathered at two expert meetings to develop global best
practice recommendations, which are presented here.
2. Methodology
The expert group (reflected in the authorship) included 18 clinicians
with expertise in the management of PKU with sapropterin dihy-
drochloride from Argentina, Australia, Austria, Brazil, France,
Germany, Italy, The Netherlands, Russia, Spain, Taiwan, Turkey, the
United Kingdom, and the USA. At the first meeting (Madrid, Spain; June
20, 2017), the experts discussed regional differences and similarities in
current response testing practices based on the results of a literature
review (Additional file 1e), the outcomes of the Global BH4 Response
Survey (Additional file 2), and case reports presented by the experts
(Additional file 3). Based on the discussions during the first meeting,
statements were developed. These statements were subsequently sent to
all participants as an online survey for consensus evaluation, using a 7-
level rating system (strongly agree, agree, somewhat agree, neither
agree nor disagree, somewhat disagree, disagree, strongly disagree),
before the second meeting (Additional file 4). Percent agreement was
defined as the percentage of participants selecting “strongly agree” or
“agree” in the pre-meeting survey. The outcomes of the pre-meeting
survey were presented at the second consensus meeting (London, UK;
December 12, 2017). All statements that achieved< 70% agreement in
the pre-meeting survey were further discussed and fine-tuned during
workshops (in three smaller groups) and subsequently presented and
discussed by all participants. The accepted statements (achieving
≥70% agreement) and the revised statements developed during the
second consensus meetings were sent to all participants after the
meeting for additional comments. The best practice recommendations
presented below include the final statements, as well as any associated
caveats, and a summary of the rationale behind the statements. Best
practice recommendations for sapropterin dihydrochloride response
testing were prepared for three patient groups: (1) neonates, (2)
non‑neonatal infants, children, adolescents, and adults, and (3) preg-
nant women, and are discussed separately. Recommendations applying
to all three patient groups are discussed as “general”.
3. Best practice recommendations
3.1. General
Key recommendations: Generala
• Both early- and late-treated PKU patients can benefit from sapropterin dihy-
drochloride
• Although PKU patients with certain mutations are more likely to respond to
sapropterin dihydrochloride, no patients should be excluded from a response test
(either a short response test or a longer treatment trial), except those with two null
mutations
• The primary population to receive a sapropterin dihydrochloride response test are
those with untreated blood Phe concentrations >360 and < 2000 μmol/L,
although there may be exceptions
• Patients with an untreated blood Phe concentration > 2000 μmol/L should be
initiated on a Phe-restricted diet as soon as possible
• If the response test is performed, efforts to collect relevant medical history,
nutritional history, and social history information should be made before saprop-
terin dihydrochloride response testing
a Any caveats and further details regarding these recommendations are dis-
cussed in the text.
3.1.1. Testing criteria
Taking into account findings from literature and clinical practice,
the experts agreed that PKU patients should not be excluded from sa-
propterin dihydrochloride response testing based on age or blood Phe
concentration. An exception was made for patients with untreated
blood Phe concentrations< 360 μmol/L or> 2000 μmol/L, although it
can be justified to perform a response test in neonates with blood
Phe<360 μmol/L under certain circumstances (see section on neonatal
patients).
The lower (untreated) blood Phe limit of 360 μmol/L recommended
for sapropterin dihydrochloride responsiveness testing is in line with
statements in the European and American PKU management guidelines.
According to these guidelines, patients with untreated blood Phe con-
centrations below 360 μmol/L do not require treatment, as they are
already in the target range [2,3]. The upper blood Phe limit for re-
sponse testing of 2000 μmol/L was set based on the experts' clinical
experience that patients with Phe concentrations above this threshold
are unlikely to respond to sapropterin dihydrochloride. In these pa-
tients, dietary treatment should be started as soon as possible. Response
testing might occasionally be considered in patients with baseline blood
Table 1
Summary of international guidelines on sapropterin dihydrochloride/BH4 response testing.
Europe [2,6,47] USA [3,48]
Patient selection All PKU patients except those:
• without 2 known null mutations (no response)• with 2 known BH4-responsive mutations (systematic response)
All PAH-deficient patients, except those with 2 null mutations in trans
Sapropterin dihydrochloride dose 20mg/kg/day 20mg/kg/day
Test duration 48 h (24 h in neonates), followed by a trial of ≤6months 4 weeksa
Definition of responsiveness Increase natural protein ≥100% or >75% of Phe levels in target
range in previously uncontrolled patients
Decrease blood Phe ≥30% or improvement in neuropsychiatric
symptoms or increase in Phe tolerance
a If testing is to be done in early infancy, the American College of Medical Genetics and Genomics (ACMG) guidelines recommend to lower blood Phe level first to
480–600 μmol/L. Blood samples for Phe determination are taken at 24 h, 1 week, 2 weeks, and in some cases, 3 or 4 weeks.
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Phe> 2000 μmol/L, depending on how Phe levels evolve over time
(higher Phe levels in HPA patients or a milder presentation than ex-
pected in an initially severe case).
When the patient's genotype is known, it can give clues about the
likelihood of sapropterin dihydrochloride response. The PAH activity
landscapes website (http://pah-activitylandscapes.org/) shows fre-
quency of genotypes by country, and links to clinical and response data
[49]. In a large retrospective study by Wettstein et al., using data from
4181 patients from the BIOPKU database, genotype could predict re-
sponsiveness in 71% of cases [24]. Genotyping can also help decide
whether a response test is indicated and which test duration is most
suitable. A sapropterin dihydrochloride test is not recommended for
patients with two null mutations, as these patients are very unlikely to
respond [24]. This recommendation is largely in line with the European
and American guidelines for the management of PKU (Table 1) [2,3]. In
all other patients, a response test remains the best method to determine
responsiveness. It should be noted that the presence of two null mu-
tations can generally not be used as a selection criterion for neonatal
patients identified with newborn screening, as information on genotype
is usually not available at the time of sapropterin dihydrochloride re-
sponse testing.
3.1.2. Collection of medical, nutritional, and social history data
Before a sapropterin dihydrochloride response test, efforts should be
made to collect medical and social history data that could prohibit or
influence responsiveness to the drug. Relevant medical history data
include physical and neurological exam data, medical issues (including
allergies), (birth) anthropometrics, concomitant medications, and re-
levant laboratory data. Anthropometric data, including growth history,
are important because of the negative impact PKU can have on physical
growth, body stature, and body composition [50,51]. In non‑neonatal
infants, children, adolescents, and adults, blood Phe history (average
blood Phe concentration and variability), Tyr status (average blood Tyr
concentration relative to the normal range and Phe:Tyr ratio), devel-
opmental history, and neurocognitive status should be collected as well.
Information on a patient's neurocognitive status is important to identify
the need for any additional assistance or needs during the test. The
ability to adhere to treatment is key, especially for adolescent and adult
patients, as they are responsible for taking their medication daily. Fo-
late, B12, and micronutrient status may also be considered as part of the
baseline assessment. Medical history data that should be collected in
pregnant women with PKU are the same as for non-pregnant patients.
However, although a neurocognitive test can be performed in women
who are planning pregnancy, it should not be performed in pregnant
patients if it delays treatment. In addition, the same medical history
data as for pregnant healthy women should be collected, including
obstetric/gynecologic history (number of weeks gestation, first child or
not, ultrasounds, considered high risk pregnancy), and enteral toler-
ance.
Important nutritional history data to collect in neonates include the
method of feeding (breastfeeding or formula feeding) and frequency of
feeding (for total volume calculation). Other nutritional history data
such as outcomes of standard pediatric assessments of infant feeding
abilities and mother-child feeding dynamics may also be useful, parti-
cularly if retesting is required later. In non‑neonatal patients, in-
formation on dietary history, feeding skills (in children), Phe tolerance,
possible food phobias, use of medical foods/amino acid supplements,
low protein foods, and supplements (e.g. tyrosine, vitamin/mineral),
and treatment adherence should be collected.
Social history information that should be collected includes the
distance to the clinic, and insurance coverage of e.g. medical foods and
low protein foods. In addition, family dynamics should be documented
for children, while for adults their living situation and support system,
school history, and employment history/status are relevant. However,
treatment should not be delayed for the collection of information that
will not affect patient care.
3.2. Neonatal patients
Key recommendations for sapropterin dihydrochloride response testing in neonatesa
• Neonates with an untreated blood Phe concentration of 360–2000 μmol/L should
receive a sapropterin dihydrochloride response test for testing BH4 responsiveness;
testing of patients with blood Phe < 360 μmol/L could be considered to rule out
most disorders of BH4 metabolism; patients with blood Phe > 2000 μmol/L should
not typically be tested, but should be initiated on a Phe-restricted diet immediately
• Although a test should be administered as soon as possible after birth, efforts should
be made to collect baseline information before sapropterin dihydrochloride
response testing in neonates, including blood Phe concentration and body weight
(for determining dose); in addition, it may be useful to estimate Phe intake
• Parent education before sapropterin dihydrochloride testing in neonates should
include: setting of expectations of the trial, establishment of requirements for an
accurate trial, and review of treatment goals
• A response test in neonates should be performed with 20mg/kg sapropterin
dihydrochloride (crushed tablets or powder mixed in a small amount of formula or
breast milk)
• During sapropterin dihydrochloride testing in neonates, blood Phe concentration
should (initially) be monitored over a 24-h period. During this period, it is best
practice to collect samples for determining blood Phe concentration just prior, and
at 4 h, 8 h, 12 h, 16 h, and 24 h after administering sapropterin dihydrochloride
• A neonate with a decrease in blood Phe ≥30% during 24-h response testing can be
considered a sapropterin dihydrochloride responder
• In neonates identified as responsive, sapropterin dihydrochloride dose should be
adjusted between 5 and 20mg/kg/day
• Critical evaluation of clinical benefit of sapropterin dihydrochloride in neonates
should include assessment of blood Phe control, dietary Phe tolerance, need for/
amount of Phe-free amino acid supplements/medical food, and tolerability of the
drug
a Any caveats and further details regarding these recommendations are dis-
cussed in the text.
3.2.1. Timing of the neonatal test
Sapropterin dihydrochloride testing practices in neonatal patients
vary across the world: e.g., while neonatal tests are common practice in
Europe, this is not always the case in the USA [3]. If neonatal testing is
not performed, guidance for non‑neonatal infants, children, adoles-
cents, and adults should be followed (see next section).
In neonates with elevated blood Phe concentrations, treatment
(with diet and/or sapropterin dihydrochloride) before day 10 is critical,
as the intelligence quotient of PKU patients has been shown to decrease
by about 4 points for every 4 weeks delay in starting treatment [2,52].
Therefore, if a sapropterin dihydrochloride response test is considered,
it should be performed as soon as possible after birth using a test with a
maximum of 24 h.
3.2.2. Indications for testing
As previously discussed, sapropterin dihydrochloride response
testing is recommended in patients with baseline blood Phe con-
centrations between 360 and 2000 μmol/L. Only untreated blood Phe
concentrations should be used to determine the need for a test. Ideally,
the decision to test for sapropterin dihydrochloride responsiveness is
based on diagnostic blood Phe concentrations, as these may deviate
from neonatal screening concentrations. However, in countries where
diagnostic testing for PKU takes a long time due to local circumstances,
it can be justified to start sapropterin dihydrochloride based on
screening blood Phe concentrations before diagnostic concentrations
are available, to avoid any treatment delay. If diagnostic Phe con-
centrations turn out to be below 360 μmol/L, sapropterin dihy-
drochloride can be discontinued at this time. Diagnostic tests may also
reveal defects in BH4 metabolism, liver diseases, or DNAJC12 defi-
ciency which require another treatment approach [6,7]. While defects
in BH4 metabolism can in most cases be ruled out quickly by measuring
blood spot or urine pterin concentrations [53,54], diagnostic pterin
concentrations cannot be obtained quickly in some areas. In this case,
sapropterin dihydrochloride response testing may be considered also in
patients with blood Phe below 360 μmol/L to rule out disorders of BH4
metabolism. In addition, the in vivo 13C-Phenylalanine Oxidation Test,
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which quantifies PAH enzyme activity by measuring 13CO2 in exhaled
air, as described by Muntau et al. [27], can be useful to discriminate
between PKU and disorders of BH4 metabolism if diagnosis is delayed.
Although this test is relatively cheap and can be performed quickly, it is
not yet commercially available.
3.2.3. Before testing
Important baseline information to collect before response testing in
neonates includes blood Phe concentration and body weight (for de-
termining sapropterin dihydrochloride dose). Baseline blood Phe con-
centration should be collected prior to sapropterin dihydrochloride
administration and, if there is a delay between diagnosis and response
testing, on the day the drug is administered. As the exact composition of
the mother's breastmilk is unknown, it is difficult to calculate dietary
Phe intake in breastfed babies. Nevertheless, it may be useful to esti-
mate Phe intake, as it can be used as a baseline to follow the evolution
in Phe intake over the long term. Phe intake in neonates can be esti-
mated by tracking estimated fluid intake and baby's weight, considering
a mean Phe content of 40mg per 100mL mature breastmilk. If the test
is performed in the first 2 weeks of life, Phe content may vary between
40 and 80mg/100mL breastmilk (with higher concentrations earlier
after birth) [55].
It is important to discuss the protocol of the sapropterin dihy-
drochloride loading test with the patient's parents in advance, including
the (frequent) collection of blood samples, diet records, and safety is-
sues, and requirements for an accurate trial. For example, the patient
should not be ill or in a stressed state at the time of the loading test, as
this could influence outcomes [8,56], while the test can be influenced
by the fact that the neonate is in a catabolic or anabolic state. In regions
where access to sapropterin dihydrochloride treatment cannot be
guaranteed, parents need to be informed that the neonatal test can also
benefit their child in terms of excluding other HPA diagnoses and help
in the selection of future treatments. If the loading test is performed in
an outpatient setting, parents can be taught to collect filter paper blood
samples at home. However, this could be difficult for new parents who
are still adjusting to the PKU diagnosis for their baby. In this case,
hospitalization of the infant during the test should be considered, if
there are no legal or reimbursement constraints. In addition to the test
protocol, treatment goals should be reviewed with the parents. Parents
need to be aware that responsive patients may still require a Phe-re-
stricted diet and PKU dietary supplements in conjunction with sa-
propterin dihydrochloride, although diet will be less restrictive than
without treatment.
3.2.4. Testing protocol and outcome measures
The 24-h neonatal sapropterin dihydrochloride loading test is re-
commended to be performed with a 20mg/kg initial dose, which has
been shown to result in a higher response rate than a 10mg/kg dose in
clinical studies (Additional file 1) [19,20]. It is recommended to collect
blood samples for determining Phe concentrations at 4 h, 8 h, 12 h,
16 h, and 24 h after administering sapropterin dihydrochloride. The
experts are aware that 12 and 16 h samples for determination of blood
Phe during the 24-h test period may be difficult to collect in an out-
patient setting, and that practices vary widely between and within
countries. Nevertheless, they strongly recommended obtaining these
samples whenever possible, since late responders may show a decrease
in blood Phe concentration between 8 h and 24 h after dosing, and the
lowest Phe concentration can be missed if 12-h and/or 16-h samples are
not collected.
The experts recommend defining “responsiveness” in the neonatal
loading test as a reduction in blood Phe concentration from baseline of
at least 30%. Although arbitrary, a 30% reduction in blood Phe con-
centration from baseline is the most widely used criterion in studies and
clinical practice (see Additional files 1 and 2). After the 24 h test, sa-
propterin dihydrochloride treatment should be stopped and dietary
treatment should be started immediately until the results of the test are
known. It should be noted that a reduction in blood Phe during the test
may also occur in patients who have a deficiency in BH4 metabolism or
a DNAJC12, underlining the importance of a correct diagnosis.
In neonatal patients shown to respond, sapropterin dihydrochloride
dose should be adjusted between 5 and 20mg/kg/day over time, taking
into account changes in blood Phe concentration while the child is
growing. Dose adjustment should either lead to increased Phe toler-
ance, or to stable tolerance under a lower dose. It should be noted that
patients may have a relatively high Phe tolerance without sapropterin
dihydrochloride during the first weeks of life, which could bias long-
term results. Responsiveness to sapropterin dihydrochloride should
therefore be critically evaluated by assessing long-term control of blood
Phe, taking into account initial blood Phe concentration and genotype
(if available). Changes in dietary Phe tolerance may be monitored in
relation to the Phe intake estimated at baseline. In addition, the need
for and/or the amount of Phe-free amino acid supplements/medical
foods, as well as the tolerability of the drug, should be assessed. Dietary
Phe intake should be adapted in accordance with published re-
commendations [9].
3.3. Non‑neonatal infants, children, adolescents, and adults
Key recommendations for sapropterin dihydrochloride response testing in non‑neo-
natal infants, children, adolescents, and adultsa
• A previous BH4/sapropterin dihydrochloride response test, or an untreated blood
Phe concentration < 360 or > 2000 μmol/L in the neonatal period, should not
preclude a response test at a later age
• If a patient previously received a BH4/sapropterin dihydrochloride test, the
following information should be collected about that trial: length of the test, results
of the test, timing of the test (neonatal period or not), reason why treatment was not
started
• For non‑neonatal infants, children, adolescents, and adults, test duration should be
at least 48 h and up to 4 weeks
• Potential responsiveness in a 48-h to 7-day test can often be evaluated by measuring
the reduction in blood Phe concentration, with a≥ 30% reduction in blood Phe
indicating response; a longer trial is needed to identify an increase in Phe tolerance
(see Fig. 3 and text for protocol details and caveats)
• Baseline data that should be collected before starting sapropterin dihydrochloride
include blood Phe concentration (≥3 measurements), body weight (for determining
dose), dietary Phe intake and tolerance, amino acid supplements/medical food
intake; a neurocognitive test should be collected whenever possible
• Before starting a sapropterin dihydrochloride response trial, PKU patients and/or
parents should be educated to establish expectations of the trial and requirements
for an accurate trial, review treatment goals, and discuss the possibility to connect
with other parents/patients who have experience with sapropterin dihydrochloride
response testing and/or treatment
• A response test or trial must be performed with 20mg/kg sapropterin dihy-
drochloride (tablets, crushed tablets, or powder in liquid or soft foodsb), adminis-
tered daily at the same time of the day with a meal
• After final Phe tolerance has been determined, the sapropterin dihydrochloride dose
should be adjusted between 2 and 20mg/kg/day
• In sapropterin dihydrochloride responsive patients who have been following a Phe-
restricted diet, dietary Phe intake should be progressively increased, per published
guidelines [9]
• Critical evaluation to determine clinical benefit of sapropterin dihydrochloride
should include assessment of improvement in blood Phe control, dietary Phe
tolerance, need for special low protein foods, need for/amount of amino acid
supplements/medical food, drug tolerability, and improvements in neurocognitive
status, behavior, and/or quality of life
a Any caveats and further details regarding these recommendations are dis-
cussed in the text.
b Not all sapropterin dihydrochloride formulations may be available in dif-
ferent countries.
3.3.1. Indications for testing
Sapropterin dihydrochloride testing in non‑neonatal infants, chil-
dren, adolescents, and adults with PKU should be considered when
untreated blood Phe concentrations are above the target range, whether
they are on dietary therapy or not. However, unknown untreated blood
Phe concentrations should not preclude a sapropterin dihydrochloride
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test. As previously mentioned, blood Phe target ranges for non‑neonatal
PKU patients differ between European and American guidelines. The
European guidelines recommend keeping blood Phe below 360 μmol/L
in children until the age of 12 years, and below 600 μmol/L in older
(non-pregnant) patients [2]. American guidelines recommend
lifelong maintenance of blood Phe concentration in the range of
120–360 μmol/L [3]. Even if patients already have Phe levels within the
recommended range with diet, sapropterin dihydrochloride can help to
reduce the burden caused by a Phe-restricted diet. Patients who were
not tested in the neonatal period should be offered a response test. A
previous response test in the neonatal period should not preclude
sapropterin dihydrochloride testing later in life, particularly if the pa-
tient's genotype suggests a BH4-responsive phenotype. Slow responders
can be missed in the shorter neonatal test [25].
3.3.2. Before testing
Baseline information that should be collected before starting sa-
propterin dihydrochloride in non‑neonatal PKU patients includes blood
Phe concentration, body weight (for determining dose), dietary Phe
intake, and amino acid supplements/medical food intake. For patients
under good metabolic control, it is essential for the interpretation of the
test results to assess maximum Phe tolerance by progressively in-
creasing Phe intake prior to response testing. Assessment of maximum
Phe tolerance at baseline assures that an observed increase in Phe tol-
erance after the test is due to sapropterin dihydrochloride. In addition,
it may be valuable to perform a baseline neurocognitive test to allow
assessment of changes in neurocognitive function in the long term.
However, as no short-term effect of sapropterin dihydrochloride treat-
ment on neurocognitive function is expected, the test can also be per-
formed shortly after starting treatment. Formal psychometric evalua-
tion of neurocognitive function is best, but if not available,
neurocognitive evaluation may consist of questions on e.g. patient
performance, concentration, attention, and hyperactivity.
Similar to parents of neonatal patients, older PKU patients and/or
their parents should receive proper education before sapropterin di-
hydrochloride testing to establish expectations of the trial and re-
quirements for an accurate trial, and to review treatment goals
(Table 2).
3.3.3. Testing protocol and outcome measures
A response test in non‑neonatal individuals with PKU is preferably
performed with sapropterin dihydrochloride at 20mg/kg/day. As BH4
is water soluble, and thus not expected to be absorbed in fat tissue, the
experts suggest using ideal body weight rather than actual body weight
to calculate the dose for obese individuals.
Test duration should be at least 48 h and up to 4 weeks. Several
factors can determine the choice for a short or longer test (Fig. 3). For
patients with baseline blood Phe concentrations in the target range due
to dietary therapy, and particularly those with concentrations of
180 μmol/L or lower, a longer-term trial of 4 weeks with an increase in
maximum Phe tolerance may be most suitable (Fig. 3). These patients
do not always show a significant decline in blood Phe in a shorter re-
sponse test, even if they are responsive to sapropterin dihydrochloride
(Additional file 3) [3,26]. An increase in maximum Phe tolerance can
be determined by progressively increasing Phe intake, while keeping
the patient in the target blood Phe range. According to the European
guidelines for the diagnosis and treatment of PKU “establishing an in-
crease in natural protein tolerance of ≥100% from pre-treatment with
blood Phe concentrations remaining consistently within the target
range” after 6months provides evidence for responsiveness [8]. It
Table 2
Recommendations for parent/patient education before sapropterin dihydrochloride testing.
Establish expectations of the trial: • Collection of a sufficient number of blood samples• Diet record• Documentation of potential adverse events
Establish requirements for an accurate trial: • No fever or illness• Decreased stress• No travel plans• Standardization of blood sampling• Consistent dietary protein intake (intact and medical food/amino acid supplements) during the trial
Review treatment goals: • Set expectations of the effects of sapropterin dihydrochloride
o Some patients still need dietary protein restriction and medical food/amino acid supplements in combination with sapropterin
dihydrochloride
o A more relaxed diet can have a positive impact on the patient's life
• Parents or patients may be connected with other parents/patients who have experience with sapropterin dihydrochloride
treatment and/or a response trial
No
No Yes




Do not perform sapropterin
dihydrochloride response 
test








Blood Phe decreases ≥30%?
















Increase in Phe tolerance? No
Yes
Continue sapropterin dihydrochloride
Adjust dose if necessary
Critical evaluation to determine clinical benefit 
aA short test can also be performed if a longer trial is not possible due to local 
circumstances
bContinuing sapropterin dihydrochloride response testing for 4 weeks can be considered if 
the patient is suspected to be a responder
Fig. 3. Recommended algorithm for sapropterin dihydrochloride response
testing in non‑neonatal infants, children, adolescents, and adults with phe-
nylketonuria (PKU).
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remains to be established what increase in Phe tolerance should be
considered as a response after 4 weeks.
During a long-term sapropterin dihydrochloride response test, blood
samples for determining Phe concentrations should be collected at least
once weekly, and daily if possible. Although conditions may vary be-
tween centers, blood samples should always be collected under the
same condition, by the same method (i.e. venous vs. finger prick) and
analyzed the same way (i.e. HPLC, tandem MS) in each patient (at the
same time of the day, preferably fasted), as Phe concentrations can vary
considerably based on these factors [56]. Any illness during the trial
should be documented as it may temporarily increase Phe concentra-
tion, and thus affect trial outcomes [8,56]. An intercurrent illness
during a test can make the results uninterpretable.
Patients who have blood Phe concentrations above target range at
baseline can have a short response test (Fig. 3). A short response test
can also be considered if a long trial in a patient with blood Phe con-
centrations in the target range cannot be done due to local circum-
stances (e.g. limited access to sapropterin dihydrochloride, no re-
imbursement). Potential responsiveness in a shorter test should be
evaluated by measuring the reduction in blood Phe concentration. To
increase the likelihood of a positive response to sapropterin dihy-
drochloride in the shorter test in patients with blood Phe concentrations
in the target range, blood Phe may have to be increased before the test
by diet relaxation or Phe loading [26]. It should be noted that raising
blood Phe concentration for a response test in children with PKU under
dietary control can be problematic as parents may be reluctant to
temporarily increase their child's protein intake. Moreover, blood Phe
concentration does not always rise quickly in response to a higher Phe
intake [57]. Together, these issues can impede stabilization of blood
Phe at a sufficiently high concentration, which is necessary for correct
interpretation of the response test. Adding a source of Phe (e.g. pow-
dered milk) into the amino acid supplement/medical food to provide a
hidden source of extra Phe can be considered for the trial period.
In a shorter test, blood Phe concentration should initially be mon-
itored over a 48-h period. Samples for determining blood Phe should be
collected just prior to administering sapropterin dihydrochloride, fol-
lowed by 3–5 samples during the test period at the same time of the day
and measured by the same method. A patient who shows a decrease in
blood Phe concentration of ≥30% within 48 h can be considered a
responder. Otherwise, it can be considered to prolong testing for
1 week. During this period, blood samples for determining Phe con-
centration should attempt to be collected daily. In potential responders
(Phe reduction ≥30%), durability of response should be monitored
over an extended period of time of around 4weeks by assessing changes
in overall blood Phe control (variability in blood Phe concentration,
Phe:Tyr ratio, long-term blood Phe reduction), and dietary Phe toler-
ance. Continuing response testing for 4 weeks can also be considered if
the patient shows insufficient decrease in blood Phe in the short test,
but is suspected to be a responder based on genotype.
3.3.4. After testing
After the response test, and once final maximum Phe tolerance has
been determined, the sapropterin dihydrochloride dose should be ad-
justed between 5 and 20mg/kg/day. Ideally, sapropterin dihy-
drochloride should be administered with a meal to increase absorption,
and to minimize possible side effects due to the acidity of the drug. It
should be noted that in patients with certain mutations, higher doses
might result in a lower reduction in blood Phe than lower doses (http://
pah-activitylandscapes.org/) [49].
To critically evaluate clinical benefit of sapropterin dihydrochloride
in the long term, it is necessary to continue measuring blood Phe
control (blood Phe concentration, variability in blood Phe, Phe:Tyr
ratio), and dietary Phe tolerance. In order to determine the impact of
sapropterin dihydrochloride on Phe tolerance in the long term, it is
necessary to continue increasing Phe intake in line with published
guidelines [9]. Changes in the need for or the amount of special low
protein foods, amino acid supplements/medical foods, as well as any
tolerability issues should also be documented. Finally, changes in
neurocognitive status, behavior, and/or quality of life might be eval-
uated in the long term.
3.4. Pregnant women
Both the European and American guidelines for PKU management
recommend maintaining blood Phe concentration within the range of
120–360 μmol/L throughout pregnancy [2,3]. Exposure of unborn
children to high Phe concentrations can lead to intrauterine growth
retardation, intellectual disability, behavioral problems, microcephaly,
and congenital heart disease, depending on the timing and duration of
the exposure [58–60]. Given the serious risks for the offspring of PKU
patients, is it essential to bring blood Phe concentration≤ 360 μmol/L
as quickly as possible. Information regarding the use of sapropterin
dihydrochloride during pregnancy is limited. Available data from the
Maternal Phenylketonuria Observational Program (PKU MOMS), a sub-
registry of the Phenylketonuria Demographics Outcomes and Safety
(PKUDOS) registry, and a European cohort study showed that sa-
propterin dihydrochloride can reduce blood Phe concentration during
pregnancy and is generally well-tolerated [61,62]. According to the
experts, the considerable benefit of metabolic control for the unborn
child, together with the limited risk of teratogenicity of sapropterin
dihydrochloride use during pregnancy, justify response testing during
pregnancy when metabolic control cannot be achieved with diet alone.
However, it is strongly recommended to perform the test prior to
pregnancy, if possible.
Key recommendations for pregnant women
• Sapropterin dihydrochloride treatment should be considered in pregnant women
with PKU if
o They are unable to achieve a blood Phe concentration ≤ 360 μmol/L with dietary
management or
o They are already on sapropterin dihydrochloride, which had been started prior to
becoming pregnant, and request to continue taking this medication during
pregnancy
• The following baseline information should be collected before sapropterin dihy-
drochloride testing: blood Phe concentration (≥3 measurements, if it does not
delay treatment), pre-pregnancy body weight (for determining dose), and dietary
Phe intake and Phe tolerance
• During the sapropterin dihydrochloride test, blood Phe concentration should
(initially) be monitored over a 48-h period (see text for protocol details and caveats)
o A pregnant woman with PKU who achieves blood Phe ≤360 μmol/L within 48 h
of beginning sapropterin dihydrochloride should maintain the same diet while
continuing on sapropterin dihydrochloride
o If the blood Phe concentration≤ 360 μmol/L is not achieved within 48 h, but
there is a decrease towards this target, dietary protein intake should be adjusted
to help lower blood Phe to target while maintaining sapropterin dihydrochloride
treatment
o If the patient does not respond to sapropterin dihydrochloride within 48 h,
pharmacologic treatment should be discontinued and focus should shift to
optimizing dietary management to lowering blood Phe to the target range
• Sapropterin dihydrochloride dose should be assessed over the course of pregnancy.
The dose may decrease with increasing Phe tolerance due to fetal growth during the
third trimester of pregnancy; diet and medical food/amino acid supplements should
likewise be adjusted
• Durability of sapropterin dihydrochloride response should be monitored over an
extended period of time by monitoring blood Phe control within the target range of
120–360 μmol/L, assessing tolerability, and determining dietary intake and nutri-
tional adequacy
• If continuation of sapropterin dihydrochloride after pregnancy is considered,
clinical benefits should be reassessed in terms of blood Phe control, change in
dietary Phe tolerance, neuropsychiatric benefits, and quality of life changes
If a pregnant patient is unlikely to respond to sapropterin dihy-
drochloride (i.e. when she has a severe form of PKU, with a high di-
agnostic blood Phe concentration, or a genotype suggesting a non-re-
sponsive phenotype), it is not recommended to perform a response test.
In this case, dietary control should be started as soon as possible. If the
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target blood Phe concentration cannot be achieved with either therapy,
the patient should be hospitalized. Close monitoring of blood Phe
concentrations as well as careful antenatal care throughout pregnancy,
particularly ultrasound examinations to follow-up head circumference
and body weight of the fetus, are crucial [8].
As time is essential during pregnancy, pregnant PKU patients should
have a shorter 48-h test. This shorter test should be performed using
sapropterin dihydrochloride 20mg/kg/day, and following the same
protocol as the 48-h test described for non-pregnant patients (see re-
commendations non‑neonatal infants, children, adolescents, and
adults).
Patient education recommended for pregnant women with PKU
regarding the response test is similar to that for non-pregnant patients
(Table 2), but should also include discussion of the importance of blood
Phe control throughout the pregnancy and changing Phe tolerance
during pregnancy.
As in the neonatal period, it is essential to achieve the target blood
Phe concentration in pregnant women as quickly as possible. If the
target concentration is achieved within 48 h, the patient can continue
on sapropterin dihydrochloride with the same diet. When blood Phe
decreases, but remains above 360 μmol/L, the patient should continue
on sapropterin dihydrochloride, while her diet should be revised in line
with published guidelines to help lower blood Phe concentration to the
target range [9]. When blood Phe shows no reduction within 48 h,
pharmacologic treatment should be discontinued. A longer trial may be
performed after delivery if the patient is suspected to be a responder.
During pregnancy, the time window to test responsiveness is limited to
the first trimester, as this period is most critical for the development of
the child.
Little is currently known about the risk of taking sapropterin dihy-
drochloride during lactation for the child. More information is to be
expected from the PKU MOMS sub-registry, which collects data on
lactation in sapropterin dihydrochloride-treated women who are fol-
lowing the standard of care for pregnant women with PKU [61]. If
breastfeeding is planned, the following actions should be considered:
adjustment of dietary Phe tolerance, adjustment of the sapropterin di-
hydrochloride dose, evaluation of tolerability, and reimbursement of
the drug during breastfeeding.
4. Conclusions and future directions
Since the introduction of sapropterin dihydrochloride for the
treatment of HPA in patients with BH4-responsive PKU, a wide variety
of protocols have been proposed to assess responsiveness to the drug.
The global recommendations for the evaluation of responsiveness to
sapropterin dihydrochloride in PKU patients presented here are the
result of 10 years of research and clinical experience with the drug in
daily practice, and are expected to improve the validity and compar-
ability of response testing results worldwide. It should be noted that
while these recommendations represent “best practices” for the per-
formance of a response test, the authors are aware that some centers
will not be able to align with all recommendations due to cultural
differences, financial hurdles, and local circumstances or legislation.
However, in the experts' opinion, it is in the patients' interest that all
centers endeavor to implement these best practice recommendations,
although this may require considerable efforts and time from clinic
staffing and patients.
Mechanisms determining response to sapropterin dihydrochloride
are multifactorial and complex, and further optimization of these pro-
tocols may be required based on the outcomes of ongoing and future
research. Although genotype may be predictive of response to some
degree, other factors such as interallelic complementation, post-tran-
scriptional regulation of PAH, Phe transport into hepatocytes, and ab-
sence or presence of other enzymes involved in sapropterin dihy-
drochloride oxidation and cellular uptake such as dihydrofolate
reductase, also play an important role [63–65]. Better insight into the
interactions between these factors may allow for better prediction of
responsiveness. As long as these mechanisms are insufficiently under-
stood, a response test or trial remains the best method to identify po-
tential responders.
Continued follow-up of patients is expected to provide better insight
into the efficacy and safety of sapropterin dihydrochloride across the
disease spectrum, at different ages, during pregnancy, and in late-
treated patients, including long-term effects on neurocognitive tests,
neuropsychiatric symptoms, and growth [61,64,66]. More research is
warranted to further explore the genetic, dietary, and environmental
factors which may underlie the observed variation in responsiveness
between populations.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2019.04.004.
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